OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Reviews is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	117
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	116
Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders	115
Editorial Board	107
Not all LGL leukemias are created equal	78
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	66
Clinical burden of hemophilia in older adults: Beyond bleeding risk	58
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	56
Radiation and leukaemia: Which leukaemias and what doses?	53
Artificial intelligence in sickle disease	53
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	51
Thalassaemia in China	47
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	45
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	40
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	38
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia	38
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	38
Chasing leukemia differentiation through induction therapy, relapse and transplantation	37
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	37
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	36
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	36
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	36
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	34
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	33
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	33

CHIPing away the progression potential of CHIP: A new reality in the making	33
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	32
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	31
Endothelial cells: major players in acute myeloid leukaemia	31
Immune thrombocytopenia: A review of upfront treatment strategies	31
Preservation of fertility in female patients with hematologic diseases	31